Kopran Ltd.

BSE: KOPRAN524280ISIN INE082A01010

Healthcare
Pharmaceuticals
BSE Healthcare

Share price

₹250.40+3.60 (+1.46%)

as of 4 Nov 2026

Prices adjusted for splits and bonuses; cash dividends excluded. Volume shows actual shares traded.

52W high: ₹295.90
52W low: ₹107.00
Off 52W high: -15.38%
1M return: -6.83%
3M return: +27.85%
6M return: +52.45%
1Y return: +52.13%
20D avg volume: 27,550
50 DMA: ₹251.48
200 DMA: ₹184.17

Key ratios Consolidated

Market cap: ₹1,210 Cr
Current price: ₹250.40
52W high / low: ₹295.90 / ₹107.00
Face value: ₹10.00
P/E: 30.79
P/B: 2.29
EPS (TTM): ₹8.13
Book value / share: ₹109.25
ROE: —
ROCE: 8.00%
Operating margin: —
Net margin: —
Debt / equity: 0.29
Net debt: ₹152.01 Cr
Interest cover: 4.28
Dividend yield: 1.20%
Dividend / share (TTM): ₹3.00
Payout: 36.90%
Cash conversion cycle: 144.2 days

Financials

Metric	Q2 FY27	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24
Income statement
	211.26	153.99	234.02	194.28	117.91	135.22	172.36	166.24	151.56	139.44	186.08	158.92
	0.62	2.05	0.09	0.07	0.03	2.56	3.26	0.17	0.99	2.63	9.67	2.43
	211.89	156.05	234.11	194.35	117.94	137.77	175.62	166.41	152.56	142.06	195.75	161.35
	205.99	147.25	208.76	183.60	129.56	127.88	161.91	152.56	142.91	127.33	170.57	140.84
	136.03	120.89	139.93	117.87	93.08	80.30	109.20	96.75	103.54	91.51	108.94	108.91
	0.69	4.20	1.84	1.23	0.28	0.39	7.77	0.42	0.99	0.49	4.21	2.26
	20.18	18.46	16.46	16.57	16.76	15.43	17.26	15.40	14.53	13.35	12.92	13.74
	4.25	3.28	3.17	2.67	2.09	2.54	2.77	2.16	2.23	2.18	2.59	2.24
	5.89	5.77	4.52	4.42	4.28	4.26	3.87	4.00	3.85	3.87	3.59	3.27
	34.16	28.56	38.07	28.89	30.42	20.25	22.65	25.30	24.64	22.03	23.66	21.97
	5.89	8.80	25.35	10.74	-11.63	9.89	13.71	13.86	9.64	14.73	25.18	20.51
	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	5.89	8.80	25.35	10.74	-11.63	9.89	13.71	13.86	9.64	14.73	25.18	20.51
	1.50	2.10	6.48	1.41	-1.70	2.44	4.03	3.46	2.26	3.64	6.56	4.71
	4.39	6.70	18.87	9.34	-9.92	7.45	9.68	10.39	7.38	11.10	18.62	15.79
	0.91	1.39	3.91	1.93	-2.06	1.54	2.01	—	1.53	2.30	3.86	3.28
Key metrics
	16.03	17.85	33.04	17.83	-5.26	16.69	20.35	20.02	15.72	20.78	31.36	26.02
	7.60%	11.60%	14.10%	9.20%	-4.50%	12.30%	11.80%	12.00%	10.40%	14.90%	16.90%	16.40%
	2.10%	4.40%	8.10%	4.80%	-8.40%	5.50%	5.60%	6.20%	4.90%	8.00%	10.00%	9.90%
	1.70%	—	5.10%	—	-1.80%	—	2.80%	—	—	—	—	—
	79.20%	13.90%	35.80%	16.90%	-22.20%	-3.00%	-7.40%	4.60%	—	—	—	—
	144.30%	-10.10%	94.90%	-10.10%	-234.40%	-32.90%	-48.00%	-34.20%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22
Income statement
	793.55	681.42	629.60	614.59	550.99	477.52
	2.83	0.35	3.98	14.61	3.06	10.61
	796.40	681.77	633.59	629.20	554.05	488.13
	745.60	647.41	581.64	561.66	517.99	406.35
	514.72	431.18	401.00	394.85	321.61	297.33
	7.96	3.74	9.66	6.03	24.34	3.23
	71.67	65.21	60.54	52.28	49.95	43.27
	13.37	10.47	9.34	8.59	6.08	5.12
	20.60	17.47	15.59	12.89	12.71	11.10
	129.68	115.24	91.55	85.95	—	75.48
	50.78	34.36	51.95	67.55	36.07	81.78
	0.00	0.00	0.00	0.00	0.00	0.00
	50.78	34.36	51.95	67.55	36.07	81.78
	11.49	8.62	13.40	16.59	8.83	20.75
	39.30	25.73	38.55	50.96	27.23	61.03
	8.14	5.33	7.99	10.57	5.65	13.77
Key metrics
	84.75	62.30	76.88	89.03	54.86	98.00
	10.68%	9.10%	12.20%	14.50%	10.00%	20.50%
	4.95%	3.80%	6.10%	8.30%	4.90%	12.80%
	—	8.00%	10.40%	—	—	—
	34.11%	8.20%	2.40%	11.50%	15.40%	—
	123.30%	-33.30%	-24.40%	87.10%	-55.40%	—
	—	8.27	-13.03	—	—	—
	—	2.59	1.09	—	—	—
	—	0.29	0.29	—	—	—
	—	152.01	128.31	—	—	—
	—	144.2	153.6	—	—	—
Balance sheet
	—	908.36	844.01	—	—	—
	—	523.18	509.75	—	—	—
	—	0.68	19.47	—	—	—
	—	262.66	214.93	—	—	—
	—	164.21	169.42	—	—	—
	—	79.34	89.67	—	—	—
	—	337.05	196.65	—	—	—
	—	157.82	119.41	—	—	—
	—	346.18	252.34	—	—	—
	—	152.69	147.78	—	—	—
	—	138.74	131.30	—	—	—
	—	13.95	16.48	—	—	—
	—	530.28	518.35	—	—	—
Cash flow
	—	66.75	41.87	—	—	—
	—	-64.60	-56.43	—	—	—
	—	-20.94	25.87	—	—	—
	—	58.48	54.90	—	—	—

Metric	Q2 FY27	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24
Income statement
	87.12	62.76	118.04	93.88	42.39	51.34	75.94	71.94	73.53	49.61	90.62	82.33
	0.86	2.91	1.00	0.32	0.32	1.80	1.92	0.75	1.12	2.12	8.15	1.29
	87.98	65.67	119.04	94.20	42.71	53.13	77.85	72.68	74.65	51.73	98.77	83.62
	79.57	56.89	93.97	78.62	47.58	48.52	66.14	62.86	65.90	46.22	78.22	72.47
	45.61	37.55	58.28	51.05	26.19	27.36	43.88	36.01	41.91	31.84	56.74	48.04
	0.69	4.28	1.58	1.23	0.28	0.39	2.63	0.42	1.32	1.22	1.35	0.61
	10.06	8.83	8.36	8.41	8.83	7.35	8.86	7.41	7.39	6.36	6.35	6.77
	1.39	1.24	1.17	1.16	0.83	1.04	1.26	0.99	0.83	0.69	1.78	1.02
	1.39	1.35	1.34	1.25	1.16	1.22	1.24	1.33	1.23	1.20	1.16	1.17
	17.53	13.94	18.87	15.05	13.28	9.24	11.03	10.91	12.98	10.04	11.97	12.34
	8.41	8.78	25.07	15.58	-4.87	4.61	11.71	9.83	8.75	5.51	20.55	11.16
	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—	—	—
	8.41	8.78	25.07	15.58	-4.87	4.61	11.71	9.83	8.75	5.51	20.55	11.16
	2.12	2.06	6.33	3.45	0.88	1.09	3.11	2.42	2.14	1.27	5.24	2.65
	6.29	6.72	18.74	12.13	-3.99	3.52	8.60	7.41	6.60	4.25	15.31	8.51
	1.30	1.39	3.88	2.51	-0.83	0.73	1.78	1.54	1.37	0.88	3.18	1.77
Key metrics
	11.19	11.37	27.58	17.99	-2.88	6.87	14.21	12.15	10.81	7.40	23.49	13.35
	12.80%	18.10%	23.40%	19.20%	-6.80%	13.40%	18.70%	16.90%	14.70%	14.90%	25.90%	16.20%
	7.20%	10.70%	15.90%	12.90%	-9.40%	6.90%	11.30%	10.30%	9.00%	8.60%	16.90%	10.30%
	2.10%	—	5.70%	—	-0.90%	—	2.90%	—	—	—	—	—
	105.50%	22.20%	55.40%	30.50%	-42.40%	3.50%	-16.20%	-12.60%	—	—	—	—
	257.60%	90.90%	117.90%	63.70%	-160.50%	-17.20%	-43.80%	-12.90%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22
Income statement
	361.80	305.65	271.01	337.46	273.10	204.52
	5.09	2.00	5.90	16.71	16.09	8.03
	366.89	307.65	276.91	354.17	289.18	212.55
	309.05	267.25	241.12	309.65	252.27	196.38
	192.49	162.87	153.63	217.54	137.41	128.52
	7.78	3.47	5.59	14.36	36.73	3.23
	35.66	32.94	30.02	25.61	25.15	21.05
	4.96	4.20	3.77	4.50	2.67	2.95
	5.33	4.98	5.00	4.62	4.41	4.32
	65.39	54.99	44.96	44.77	42.34	40.23
	57.84	40.39	35.80	44.52	36.91	16.16
	0.00	0.00	0.00	—	—	—
	57.84	40.39	35.80	44.52	36.91	16.16
	13.96	9.99	8.94	9.88	5.66	4.42
	43.88	30.40	26.86	34.64	31.25	11.74
	9.08	6.30	5.57	7.18	6.48	2.65
Key metrics
	68.13	49.57	44.57	53.64	43.99	23.43
	18.83%	16.20%	16.40%	15.90%	16.10%	11.50%
	12.13%	9.90%	9.90%	10.30%	11.40%	5.70%
	—	9.70%	8.90%	—	—	—
	49.75%	12.80%	-19.70%	23.60%	33.50%	—
	182.37%	13.20%	-22.50%	10.80%	166.20%	—
	—	6.21	6.75	—	—	—
	—	0.98	0.87	—	—	—
	—	0.10	0.11	—	—	—
	—	46.13	26.13	—	—	—
	—	146.5	136.3	—	—	—
Balance sheet
	—	605.89	546.48	—	—	—
	—	240.24	209.05	—	—	—
	—	0.22	19.18	—	—	—
	—	132.58	91.92	—	—	—
	—	65.85	55.75	—	—	—
	—	—	36.22	—	—	—
	—	81.70	61.20	—	—	—
	—	75.74	46.49	—	—	—
	—	146.94	103.33	—	—	—
	—	46.35	45.31	—	—	—
	—	43.24	41.75	—	—	—
	—	3.11	3.56	—	—	—
	—	447.83	431.44	—	—	—
Cash flow
	—	29.66	23.30	—	—	—
	—	-30.08	-15.41	—	—	—
	—	-18.53	5.64	—	—	—
	—	23.45	16.55	—	—	—

Compounded growth

Standalone

Sales CAGR 3Y: +3.82%
Sales CAGR 5Y: —
Profit CAGR 3Y: -0.92%
Profit CAGR 5Y: —
Sales YoY (TTM): +49.75%
Profit YoY (TTM): +182.37%

Consolidated

Sales CAGR 3Y: +7.34%
Sales CAGR 5Y: —
Profit CAGR 3Y: -1.87%
Profit CAGR 5Y: —
Sales YoY (TTM): +34.11%
Profit YoY (TTM): +123.30%

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 30 Sep 2026

Promoter holding: 41.83%

Holder	Type	Holding	Previous	Change
ORICON ENTERPRISES LIMITED	Promoter Group	12.87%	—	—
PANORAMA FINVEST PVT LTD	Promoter Group	7.86%	—	—
SARVAMANGAL MERCANTILE CO LTD	Promoter Group	6.36%	—	—
ORIENTAL ENTERPRISES (SURENDRA SOMANI)	Promoter Group	3.65%	—	—
VARUN SURENDRA SOMANI	Promoter	3.57%	—	—
VANDANA SOMANI	Promoter Group	2.00%	—	—
SURENDRA SOMANI	Promoter	1.99%	—	—
PARIJAT SHIPPING AND FINALE LTD.	Promoter Group	1.89%	—	—
MADHURI MADHUSUDAN KELA	Public	1.72%	—	—
UNITED SHIPPERS LTD	Promoter Group	1.64%	—	—
ZAKI ABBAS NASSER	Public	1.62%	—	—
LAXMINARAYAN VYAPAAR P LTD	Public	1.55%	—	—
NISARG AJAYKUMAR VAKHARIA	Public	1.50%	—	—
KRISHNAMURTHY C G	Public	1.17%	—	—
KOPRAN LIFESTYLE LIMITED	Promoter Group	0.00%	—	—

Public shareholders are disclosed individually only above 1%.

Peer comparison

Company	Mkt cap (₹ Cr)	Price (₹)	P/E	ROCE	Sales YoY	Profit YoY	1Y return
Sun Pharmaceutical Industries Ltd.	4,26,112	1,776.00	38.78	17.90%	+12.13% TTM	+4.79% TTM	+4.92%
Divi's Laboratories Ltd.	2,66,424	10,036.00	91.09	19.00%	+16.35% TTM	+26.84% TTM	+47.61%
Torrent Pharmaceuticals Ltd.	1,79,908	4,730.00	85.71	9.10%	+42.06% TTM	-1.92% TTM	+32.24%
Laurus Labs Limited	1,24,601	2,306.10	93.53	19.70%	+23.03% TTM	+95.38% TTM	+134.59%
Zydus Lifesciences Limited	1,18,703	1,190.00	25.85	19.20%	+21.11% TTM	-2.51% TTM	+22.32%
Dr. Reddy's Laboratories Ltd.	1,14,513	1,372.00	41.50	13.90%	-3.53% TTM	-51.90% TTM	+14.26%
Cipla Ltd.	1,13,110	1,400.10	39.63	14.90%	-0.74% TTM	-47.48% TTM	-6.88%
Mankind Pharma Limited	1,04,631	2,533.15	46.22	13.70%	+13.27% TTM	+27.60% TTM	+6.91%
Aurobindo Pharma Ltd.	97,878	1,701.10	26.38	13.60%	+9.09% TTM	+9.48% TTM	+47.79%
Lupin Ltd	92,145	2,015.00	17.65	28.40%	+24.22% TTM	+20.10% TTM	+0.84%
Glenmark Pharmaceuticals ltd	70,608	2,501.85	39.27	16.20%	+32.94% TTM	+138.48% TTM	+35.48%
Alkem Laboratories Limited	62,054	5,190.00	28.15	18.80%	+13.36% TTM	-5.52% TTM	-8.38%
Abbott India Ltd. S	57,685	27,146.85	35.73	41.90%	+6.29% TTM	+11.18% TTM	-7.56%
Biocon Ltd.	56,061	344.00	134.63	2.90%	+5.70% TTM	-55.37% TTM	-9.53%
Gland Pharma Limited	52,105	3,157.70	46.16	13.70%	+17.57% TTM	+46.55% TTM	+65.09%
Ipca Laboratories Ltd.	50,051	1,973.15	36.40	16.40%	+10.59% TTM	+67.91% TTM	+52.33%
GlaxoSmithkline Pharmaceuticals Ltd.	42,904	2,532.60	37.42	55.40%	+12.12% TTM	+20.03% TTM	-4.84%
Ajanta Pharma Ltd.	41,406	3,313.55	32.79	29.40%	+25.01% TTM	+29.70% TTM	+26.89%
Emcure Pharmaceuticals Limited	41,254	2,174.55	37.75	25.10%	+21.12% TTM	+33.34% TTM	+64.07%
J.B. Chemicals & Pharmaceuticals Lt	38,731	2,412.25	47.77	21.90%	+5.87% TTM	+7.56% TTM	+45.79%
Sai Life Sciences Limited	32,855	1,546.30	90.80	18.10%	—	—	+67.49%
PIRAMAL PHARMA LIMITED	31,659	237.80	-151.21	0.80%	+9.43% TTM	-781.93% TTM	+18.60%
ACUTAAS CHEMICALS LIMITED	30,928	3,777.65	70.51	27.70%	+45.18% TTM	+95.78% TTM	+106.30%
Wockhardt Ltd	30,869	1,899.80	76.22	6.40%	+25.70% TTM	+894.12% TTM	+39.18%
RUBICON RESEARCH LIMITED	28,416	1,716.55	98.59	24.30%	—	—	+164.06%
Kopran Ltd.	1,210	250.40	30.79	8.00%	+34.11% TTM	+123.30% TTM	+52.13%

Filings & corporate actions

Recent announcements

Investor Presentation on Q2 FY 2026-27 Results3 Nov 2026 · Company Update / Investor Presentation
Unaudited Results for Q2 FY 2026-273 Nov 2026 · Board Meeting / Outcome of Board Meeting
Unaudited results for second quarter ended September 30,20263 Nov 2026 · Result / Financial Results
Kopran Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/11/2026 ,inter alia, to consider and approve Standalone and Consolidated Unaudited ....26 Oct 2026 · Board Meeting / Board Meeting
Medicine Authority European Union (EU)- conducted GMP inspection at Company''s Formulation manufacturing facility located at Khopoli is successfully concluded.22 Oct 2026 · Company Update / Press Release / Media Release
For the Quarter ended September 30, 202612 Oct 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Sarvamangal Mercantile Company Ltd1 Oct 2026 · Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Closure of trading window for Q2 Fy 2026-27 unaudited results25 Sep 2026 · Insider Trading / SAST / Closure of Trading Window
Price Movement22 Sep 2026 · Company Update / General
The Exchange has sought clarification from Kopran Ltd on September 21, 2026 with reference to significant movement in price, in order to ensure that investors have latest relevant information ....21 Sep 2026 · Company Update / Clarification
Allotment of ESOP Shares16 Sep 2026 · Company Update / Allotment of ESOP / ESPS
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for United Shippers Ltd8 Sep 2026 · Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Clarification for Increase in volume across exchanges1 Sep 2026 · Company Update / General
The Exchange has sought clarification from Kopran Ltd on September 01, 2026, with reference to Movement in Volume. <BR><BR>The reply is awaited.1 Sep 2026 · Company Update / Clarification
Proceedings of AGM, Voting results and Scrutinzer report18 Aug 2026 · AGM/EGM / AGM
Result Q1 FY 2026-2710 Aug 2026 · Company Update / Newspaper Publication
For Q1 FY 2026-277 Aug 2026 · Company Update / Investor Presentation
Unaudited Standalone and Consolidated Result for the quarter ended June 30, 20267 Aug 2026 · Result / Financial Results
Unaudited Standalone and Consolidated Result for the Quarter Ended June 30, 20267 Aug 2026 · Board Meeting / Outcome of Board Meeting
Annual report 202625 Jul 2026 · Others / Reg. 34 (1) Annual Report
Kopran Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/08/2026 ,inter alia, to consider and approve Results for the Q1 FY 2026-2722 Jul 2026 · Board Meeting / Board Meeting
Newspaper Publication in FORM CAA3 as per NCLT direction20 Jul 2026 · Company Update / Newspaper Publication
Record Date for Payment of Dividend16 Jul 2026 · Corp. Action / Record Date
for the Quarter 1 FY 2026-279 Jul 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Appointment of Mr. Vijay L Thange as Chief Technical Officer (CTO) of the Company.26 Jun 2026 · Company Update / Change in Management
Closure of Trading Window for Q1 FY 2026-2724 Jun 2026 · Insider Trading / SAST / Closure of Trading Window
Outcome of NCLT convened meeting for equity shareholders, secured creditor and unsecured creditor held on 03.06.20264 Jun 2026 · AGM/EGM / Court Convened Meeting
Annual Secretarial Compliance Report for the year ended March 31, 202622 May 2026 · Company Update / Reg.24(A)-Annual Secretarial Compliance
Newspaper Advertisement for the Q4 Results FY 2025-2621 May 2026 · Company Update / Newspaper Publication
Investor presentation for 2026.20 May 2026 · Company Update / Investor Presentation
Standalone and Consolidated Audited Financial result for the Fourth quarter and Year ended on March 31, 2026.19 May 2026 · Board Meeting / Outcome of Board Meeting
Appointment of Director & Issue of shares in Subsidiary company Kopran Research laboratories ltd18 May 2026 · Company Update / Change in Management
Notice of shareholders meeting convened by NCLT to be held on June 03,20267 May 2026 · AGM/EGM / Court Convened Meeting
Kopran Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 19/05/2026 ,inter alia, to consider and approve Standalone and Consolidated Audited ....6 May 2026 · Board Meeting / Board Meeting
Newspaper Advertisement pursuant to NCLT Order dated April 09, 2026 Mumbai Bench, for Notice served to the members, creditors, for the approval of Scheme of Amalgamation.4 May 2026 · Company Update / Newspaper Publication
Notice convening the Meeting of Equity Shareholders, Secured and Unsecured Creditors of Transferee and Transferor Company pursuant to NCLT order dated April 09, 2026.30 Apr 2026 · AGM/EGM / Court Convened Meeting
Pronouncement of NCLT order dated April 09, 2026 for Scheme of Amalgamation.10 Apr 2026 · Company Update / Scheme of Arrangement
Clarification on Price Movement10 Apr 2026 · Company Update / General
The Exchange has sought clarification from Kopran Ltd on April 9, 2026 with reference to significant movement in price, in order to ensure that investors have latest relevant information ....10 Apr 2026 · Company Update / Clarification
Compliance Certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018 for the Quarter ended March 31, 2026.9 Apr 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

Corporate actions

Purpose	Ex date	Record date	Payment date
Final Dividend - Rs. - 3.0000	11 Aug 2026	11 Aug 2026	—
Final Dividend - Rs. - 3.0000	4 Sep 2025	4 Sep 2025	—
Final Dividend - Rs. - 3.0000	2 Sep 2024	—	—

Board meetings

3 Nov 2026 Board Meeting - Financial Results
7 Aug 2026 Board Meeting - Financial Results